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INTRODUCTION
Obesity has been considered a worldwide epidemic, and projec-
tions indicate that by 2030, 55 million individuals will die because of 
obesity(11,13,19). Developing countries, such as Brazil, are experienc-
ing an alarming growth of obesity and chronic non-communicable 
diseases. Data from the Ministry of  Health show that 50.8% of 
Brazilian adults (men=54.7% and women=47.4%) are overweight(3). 
And both behavior modification therapy and drug therapy have low 
adherence. So, gastric bypass has shown effective results in both 
reducing weight and improving comorbidities.
Obesity is closely related with increased risk of morbidity and 
mortality in 44% of cases of type 2 diabetes (T2DM), 23% of all 
cases of cardiovascular disease (CVD)(12,20). In addition, the problem 
of obesity arises out of the fact that some obese individuals exhibit 
a set of cardiometabolic risk factors called Metabolic Syndrome 
(MetS)(19). Such factors include mainly carbohydrate metabolism 
disorders (hyperinsulinemia, insulin resistance, T2DM and intol-
erance of glucose and fats (increased triglycerides and decreased 
high-density lipoprotein [HDL-c]), abdominal obesity, high blood 
pressure (hypertension), and coagulation disorders(1).
In addition, studies have shown that treatments that involve 
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lifestyle changes are promising, such as adopting a healthy, bal-
anced diet and regular physical exercise to reduce weight and the 
components of MetS. However, the literature has recently shown 
that for obese class II and III MetS patients, neither behavior and 
lifestyle modification nor even drug therapy show good clinical 
results because such treatments have relatively poor success and 
especially poor adherence(9). Therefore, bariatric surgery is recom-
mended not only for weight loss but also for the treatment of 
T2DM, hypertension, and dyslipidemias, being the most effective 
treatment(9).
Roux-en-Y Gastric Bypass Surgery (RYGB) is currently excel-
lent technique due to weight loss and improvement in long-term 
comorbidities. Most importantly, the RYGB promotes reduced 
secretion of hormones such as ghrelin, insulin, and leptin, which 
are related to appetite, weight gain, energy balance, and metabolism 
and storage, respectively, and play a central role in the reduction 
of obesity and associated comorbidities(9).
The favorable effects of  this gastric surgical intervention on 
MetS components are evidenced in some studies. For example, in 
a longitudinal analysis of cardiovascular parameters after gastric 
bypass surgery, in 937 subjects, Dallal et al.(5) concluded that the 
procedure resulted in dramatic improvement in cardiovascular 
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risk factors. In addition, in a cohort study of 131 diabetic patients 
who underwent RYGB, Aminian et al.(2) demonstrate a remark-
able control of T2DM, dyslipidemias, and hypertension, which is 
associated with a reduction in the risk of complications such as 
nephropathy, retinopathy, and CVD. Significant weight loss, and 
cardiometabolic disease risk reduction, was observed among 633 
Hispanic adults(6). However, studies evaluating the impact of RYGB 
on drugs’ use are still lacking.
In this context, this study aimed to evaluate the impact of 
RYGB on both MetS components and the use of associated drugs 
in obese patients.
METHODS
A retrospective cohort study was performed.
Population and sample
The population studied included obese patients who underwent 
Roux-en-Y Gastric Bypass Surgery (RYGB) in the Integrated 
Center for Obesity Treatment (Centro Integrado de Tratamento da 
Obesidade – CINTRO) in the city of Porto Alegre between January 
2007 and March 2014. The sample consisted of 273 obese class II 
and class III (morbid) individuals, aged ≥20 years. All patients who 
underwent Roux-en-Y Gastric Bypass Surgery (RYGB) between 
January 2007 and March 2014 were included in the study and were 
monitored for 2 months after surgery. The individuals underwent 
gastroplasty through gastrojejunal bypass with Roux-en-Y re-
construction(17). Patients who did not return after the surgery for 
nutritional and clinical assessments were excluded.
Data collection
All of the information regarding sociodemographic and anthro-
pometric data, clinical and biochemical exams, and drugs used by 
the patients included in this study, both before and after surgery, 
were collected from the patients’ medical records. The variables 
obtained were height, weight, body mass index (BMI); MetS com-
ponents [blood pressure (BP), triglycerides (TG), HDL-c, fasting 
glucose (FG)]. MetS components were classified in accordance to 
the Third Report of the National Cholesterol Education Program 
Adult Treatment Panel NCEP-ATPIII(8) (WC >88 cm for women 
or >102 cm for men; HDL-c <50 mg/dL for women or <40 m/dL 
for men; TG >150 mg/dL; BP >130/85 mmHg; FG >110 mg/dL). 
Drugs used by the patients were obtained and classified by the 
Anatomical Therapeutic Chemical (ATC) system, which divides 
the active ingredients into different therapeutic groups according 
to their sites of  action and their pharmacological and chemical 
characteristics(21). For this purpose, the 2000 revision and updates 
were used. In ATC, drugs are classified according to their most 
important therapeutic use(21).
Statistical analysis
Data were stored in an Excel database and analyzed with 
statistical software SPSS® 17.0 version. The descriptive analysis 
was performed using frequency, central tendency, and dispersion 
measures.  The t test for paired samples was used to assess the 
equality of means of numerical variables in the pre and postopera-
tive periods, and the McNemar test was used to analyze changes in 
the frequency of categorical variables in the pre and postoperative 
periods. A 5% level was established to determine the significance 
of the tests (P≤0.005).
TABLE 1. General characteristics of obese patients who underwent RYGB
Variables N (%)
Gender 
   Female 236 (86.4)
   Male 37 (13.6)
Age group (years)
   20-29 64 (23.4)
   30-39 102 (37.4)
   40-49 51 (18.7)
   ≥50 56 (20.5)
Educational level
   Primary school 1 (0.4)
   Secondary school 3 (1.1)
   Higher education 134 (49.1)
   Specialization 119 (43.6)
   Masters/Ph.D. 14 (5.1)
   Vocational training course 2 (0.7)
Marital status 
   Married 172 (63.0)
   Single 74 (27.1)
   Divorced 20 (7.3)
   Widower 7 (2.6)
RYGB: Roux-en-Y gastric bypass surgery
Ethical considerations
The study was approved by the Ethics Committee on Human 
Research of  the Pontifical Catholic University of  Rio Grande 
do Sul (Pontifícia Universidade Católica do Rio Grande do Sul – 
PUCRS) (protocol no. 506.428; CAEE 23315213.7.0000.5336). The 
CINTRO researcher was asked to sign a confidentiality agreement, 
and the CINTRO coordinator was asked to sign a declaration 
authorizing the use of medical records in the research, which con-
tained information on all of the participants. All of the patients 
who entered the cohort from January 2014 to March 2014 signed 
an informed consent form.
RESULTS
The sample consisted of  273 subjects with mean age of 
38.4±11.2 years (range 20-69 years), 236 (86.4%) females and 37 
(13.6%) males, with follow-up period of 2 months (60 days) after 
surgery. The age group with the highest number of patients was 
30-39 years, with 102 individuals (37.4%). The majority of  the 
sample consisted of married individuals (63.0%) and with higher 
education (49.1%) (Table 1).
Regarding pre and postoperative results of the anthropometric 
variables, Table 2 shows that the anthropometric measurements 
(weight, BMI, and WC) showed a significant difference (P<0.001), 
60 days after bariatric surgery. The MetS components such as 
BP [diastolic blood pressure (DBP) and systolic blood pressure 
(SBP)], triglycerides (P<0.001) and fasting glucose (P=0.005) 
showed a significant reduction in their postoperative levels, except 
for HDL-c (P=0.112).
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Table 3 shows the changes in the frequency of each of the posi-
tive criteria for the diagnosis of MetS observed in the preoperative 
period and 60 days after surgery. The analyses showed that at the 
assessed range, there was a significant decrease in the frequency 
of individuals with hypertension (P=0.001), hypertriglyceridemia 
(P=0.006) and hyperglycemia (P<0.001). Only the frequency of 
individuals with altered HDL-c levels showed no significant dif-
ference (P=0.083).
Regarding the use of drugs associated with obesity and MetS, 
the results showed that after surgery, there was a significant reduc-
tion in the use of  antihypertensive drugs (P<0.001), antiobesity 
(P=0.010), hypoglycemic agents (P=0.013), lipid-lowering drugs 
(P<0.001), among others (Table 4). However, there was a signifi-
cant increase in the postoperative use of  gastroprotective drugs 
TABLE 2. Comparison of pre and postoperative (60 days after surgery) anthropometric measures, and metabolic syndrome components in obese 
patients who underwent RYGB
Pre/post
operative variables N Mean ±SD
Difference
P*









































RYGB: Roux-en-Y gastric bypass surgery. *T-test for paired samples, considering the preoperative results compared to postoperative results at 60 days; BMI: body mass index in kg/m2; WC: 
waist circumference in cm; SBP: systolic blood pressure in mmHg; DBP: diastolic blood pressure in mmHg; HDL-c: high-density lipoprotein in mg/dL; TG: triglycerides in mg/dL.
TABLE 3. Comparison of the frequency of diagnostic criteria for metabolic 
syndrome in the preoperative period and at 60 days of the postoperative 







Increased WC 84 84 (100.0) 75 (89.3) †
Hypertension 117 88 (75.2) 36 (30.8) 0.001
Low HDL-c 74 40 (54.1) 53 (71.6) 0.083
Hypertriglyceridemia 70 37 (52.9) 11 (15.7) 0.006
Hyperglycemia 55 23 (41.8) 10 (18.2) <0.001
RYGB: Roux-en-Y gastric bypass surgery. *McNemar Test; WC: waist circumference; HDL-c: 
High-density lipoprotein; † No measures of association are computed for not increased waist 
circumference, preventing an analysis.
TABLE 4. Comparison of the frequency of the use of drugs in the pre 
and postoperative period (60 days after surgery) in obese patients who 
underwent RYGB
Drugs in use † N PreoperativeN (%)
Postoperative
N (%) P*
Antihypertensive 273 156 (57.1) 14 (5.1) <0.001
Antiobesity 273 9 (3.3) 1 (0.4) 0.010
Drugs used in 
diabetes 273 29 (10.6) 16 (5.9) 0.013
Cardiac therapy 273 6 (2.2) 0 (0.0) ‡
Drugs for acids 
related disorders 273 21 (7.7) 159 (58.2) <0.001
Lipid modifying 
agent 273 21 (7.7) 1 (0.4) <0.001
Multivitamins 
combinations 271 4 (1.5) 262 (96.7) <0.001
Iron 273 3 (1.1) 126 (46.2) <0.001
RYGB: Roux-en-Y gastric bypass surgery. *McNemar Test. †The drugs were classified by the 
Anatomical Therapeutic Chemical (ATC) system recommended by the World Health Orga-
nization(21); ‡No measures of association are computed for cardiac therapy in postoperative, 
preventing an analysis.
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(P<0.001), multivitamin and mineral supplements (P<0.001), and 
iron alone (P<0.001) (Table 4). After bariatric surgery, a significant 
reduction was also observed in the number of drugs used by the 
patients that were associated with obesity and MetS. Before the 
surgery, the mean ±standard deviation (SD) of drug use was 2.1±1.9 
units, which decreased to 0.6±1.0 units after surgery, resulting in a 
mean difference ±standard error (SE) of 1.4±0.1 (95% CI=1.2-1.7) 
drugs (P<0.001). The mean ±SD of the use of vitamins, minerals 
and gastroprotective drugs creased from 0.1±0.4 to 2.3±1.1 units 
from the pre to the postoperative period, which shows a mean 
difference ±SE of -2.2±0.1 (95% CI= -2.3 and -2.0), which is also 
significant (P<0.001).
DISCUSSION
The literature has shown that weight loss decreases MetS 
markers, thus reducing risk factors for CVD, T2DM, some types 
of cancer, and skeletal abnormalities, which positively affects indi-
viduals’ quality of life(22). However, the literature also suggests that 
interventions advocating behavioral and lifestyle changes (i.e., diet 
and exercise) and drug therapy have little success and low adherence 
over time for obese class II and III patients with comorbidities(9). 
In this context, RYGB is important not only for decreasing body 
weight but also for playing the role of metabolic regulator. RYGB 
is a mixed surgery that combines malabsorption and restriction of 
food intake by bypassing a portion of the jejunum.
The results of  this study showed that RYGB had significant 
statistical and clinical impact on weight reduction, BMI, and com-
ponents of MetS, especially WC, BP, and triglyceride levels, which 
resulted in a significant reduction in the use of drugs associated 
with cardiovascular risk. It should be noted that these changes oc-
curred within a short period (60 days after surgery). However, this 
study did not observe significant changes in HDL-c level, which is 
an important component of MetS. Conversely, it was found that 
there was a significant increase in the use of vitamins, minerals, iron, 
and gastroprotective drugs after surgery, which the literature and 
clinical practice have demonstrated as the standard treatment for 
patients who have undergone bariatric surgery(4,10). It is noteworthy 
that the absorption of  some vitamins and minerals is decreased 
by several factors: restriction of  food intake, change in nutrient 
absorption, and the use of gastroprotective drugs that change the 
pH of the stomach and decrease the absorption of iron and cal-
cium. Additionally, gastroprotective drugs are associated with the 
depletion of some micronutrients, such as iron(13). Iron and folic 
acid are micronutrients that are essential for normal metabolism, 
and deficiencies of these micronutrients may cause health hazards, 
including the development of chronic diseases such as CVD(10).
Studies have shown that with the weight loss and caloric re-
striction caused by the RYGB, there is an improvement in energy 
metabolism, which results in improved regulation of  lipid mol-
ecules, appetite-regulating hormones, satiety, energy storage, and 
glycemic control(10). Thus, our findings corroborate those of  the 
literature, showing a beneficial impact not only in short-term weight 
reduction but also in the suppression of important cardiovascular 
risk factors, such as hypertension, increased WC, T2DM, and 
dyslipidemia, which combined are closely related to the increased 
mortality rate of obese individuals(15). Reduction of body-fat mass 
has an important beneficial impact on metabolism because with the 
reduction of adipose tissue, especially intra-abdominal tissue, there 
is a reduction in the inflammatory and oxidative process, which 
contributes to increased insulin sensitivity and improved regula-
tion of glucose levels, blood pressure, and lipid particles, primarily 
triglycerides. The hypoglycemic effect of bariatric surgery is most 
likely due to the improved hormone metabolism associated with 
diabetes. Bariatric surgery may affect the balance of β cells due to 
changes in the gastrointestinal tract(16). In addition, with weight 
loss and therefore improved insulin sensitivity, musculoskeletal 
tissue becomes more active, which increases energy consumption. 
Additionally, weight reduction and increased insulin sensitivity 
allow for less vasoconstriction and cardiac output, lower retention 
of sodium/water in renal tubules, and improved regulation of the 
proliferation of  smooth muscle in artery walls. These modifica-
tions have a favorable impact on the reduction of blood pressure 
levels and therefore on hypertension and the use of drugs to treat 
it. Several studies have reported that weight loss alone is the 
most effective non-pharmacological intervention for controlling 
hypertension, and even discrete weight reductions have signifi-
cantly decreased BP(7). In addition, due to the caloric restriction 
promoted by RYGB, the decreased influx of large amounts of fatty 
acids to the liver will lead to reduced gluconeogenesis, decreased 
secretion of very low-density lipoprotein (VLDL), and decreased 
insulin resistance, thus promoting improvements or even healing 
of comorbidities associated with obesity and MetS components, 
especially hypertriglyceridemia(4).
The favorable effects of gastric bypass in MetS are shown in 
some studies, including Aminian et al.(2) and Halperin et al.(11) of  
obese patients with T2DM; those studies compare bariatric surgery 
using the bypass technique with the clinical treatment of lifestyle 
changes in a randomized trial over 1 year. The authors concluded 
that although both treatments improved patients’ quality of life, 
bariatric surgery has a higher impact on weight loss and improved 
glycated hemoglobin and cardiometabolic risk levels.
In patients with obesity class I (mild obesity), T2DM and 
BMI between 30 and 35 kg/m2 who used oral hypoglycemic agents 
(and some of whom are insulin-dependent), the bypass technique 
is effective to improve these parameters. In a study by Lanzarini 
et al.(14), all patients who underwent bariatric surgery with gastric 
bypass exhibited improved glycemic control, and 93.6% met the 
criteria for T2DM remission. This study involves patients who 
underwent bypass surgery from July 2008 to October 2010 at the 
University Hospital of Santiago de Chile, with a 24-month follow-
up. Although the mean postoperative follow-up was short, it was 
evident that bariatric surgery may be more effective than the avail-
able treatments. Most importantly, studies have shown that obesity 
is closely related to the development of MetS and to decreased life 
expectancy. In this regard, a 2009 meta-analysis of 57 prospective 
studies with 894,576 European and American participants with a 
mean age of 46±11 years showed that people with BMI between 
22.5 and 25 kg/m2 have lower mortality rates compared to people 
with BMI greater than 25 kg/m2. It was found that for every 5 kg/ m2 
increase in BMI, overall mortality rate increases by 30%. When 
associated with other risk factors, this rate increased by 40% in 
cases of vascular disease and 60%-120% in cases of diabetes and its 
complications. In terms of years, obesity classes I and II (between 
30.0 and 39.9 kg/m2) decreased life expectancy by 2 to 4 years. 
In obesity class III (above 40 kg/m2), the decrease was between 8 
and 10 years(18). This evidence shows the importance of bariatric 
surgery for these individuals, not only to decrease cardiovascular 
risk factors and comorbidities but to decrease the mortality rate 
and thus to increase life expectancy.
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This study has some limitations, the most important of which 
is related to retrospective data collection from medical records. 
Another limitation of this study relates to it’s a short follow-up 
period, which does not allow to verify the long-term impact of 
surgery in the investigated parameters. However, cohort studies 
on the impact of the bypass components of MetS and the use of 
associated drugs conducted in Brazilian samples are still scarce. In 
addition, even a short follow-up study showed promising results, 
demonstrating the effectiveness of bypass in the investigated pa-
rameters, which surely will have a beneficial impact on health and 
quality of life of patients.
CONCLUSION
The results of  this study show that RYGB significantly re-
duces a patient’s weight and WC within a short period (60 days 
after surgery), improving their metabolic profile. These changes 
contribute to reducing both MetS components and the use and 
amount of  drugs taken for both obesity and MetS. Conversely, 
it is important to consider that the RYGB procedure and the 
use of  gastroprotective drugs result in lower absorption rates 
of  micronutrients such as iron. Thus, medical and nutritional 
postoperative follow-up are essential to ensure these patients’ 
continued health and quality of  life.
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